
Opus Genetics (IRD) Stock Forecast & Price Target
Opus Genetics (IRD) Analyst Ratings
Bulls say
Opus Genetics Inc. has demonstrated promising initial results in clinical trials for its gene therapies targeting inherited retinal diseases, specifically showing significant gains in visual acuity and sensitivity across various assessments in patients. The company's pipeline, particularly the APX3330 therapy for non-proliferative diabetic retinopathy, aligns well with the substantial market opportunity of approximately 10 million patients in the U.S., indicating strong commercial potential. Additionally, the anticipated data rollout for pediatric patients starting in Q3 2025, coupled with positive trends observed in older patient cohorts, provides a solid basis for future growth and investment in Opus Genetics's innovative therapeutic offerings.
Bears say
Opus Genetics Inc. faces significant risks that contribute to a negative outlook on its stock, primarily related to the commercial viability of its product pipeline. The potential failure of its gene therapies and other treatments to meet projected peak revenue targets could hinder financial performance, particularly given the competitive landscape and uncertain market dynamics. Additionally, reliance on securing adequate capital to sustain operations and advance program development raises further concerns regarding the company's financial stability and long-term success.
This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.
Opus Genetics (IRD) Analyst Forecast & Price Prediction
Start investing in Opus Genetics (IRD)
Order type
Buy in
Order amount
Est. shares
0 shares